Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol. 17. Concurrent participation in any interventional clinical trial. 18. Pregnant and nursing women. NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 5 Confidential and Proprietary 12 Products, Dosage, and Mode of Administration: Investigational Products Dosage Mode of Administration Aldoxorubicin HCl 100 mg/m2 (induction); 60 mg/m2 (maintenance) IV ETBX -011 (CEA) 1 × 1011 VP/dose SC ETBX -051 (Brachyury) 1 × 1011 VP/dose SC ETBX -061 (MUC1) 1 × 1011 VP/dose SC GI-4000 (RAS) 40 YU/dose SC GI-6207 (CEA) 40 YU/dose SC GI-6301 (Brachyury) 40 YU/dose SC haNK cells 2 × 109 cells/dose IV N-803 15 µg/kg SC Approved Products Dosage Mode of Administration Avelumab 10 mg/kg IV Bevacizumab 5 mg/kg IV Capecitabine 650 mg/m2 BID, up to a maximum of 1,000 mg per dose PO Cisplatin 32 mg/m2 IV Cyclophosphamide 25 mg BID (days 1 –5) 25 mg daily (days 8 –12) PO 5-FU 1500 mg/m2 85- to 96-hour continuous IV infusion Leucovorin 20 mg/m2 IV bolus Nab-paclitaxel 125 mg ( day 1 of induction); 100 mg ( day 15 of induction and day 1 of maintenance) IV SBRT 8 Gy maximum (exact dose to be determined by the radiation oncologist) External beam radiation Duration of Treatment: • Induction phase: Up to 1 year. • Maintenance phase: Up to 1 year.